Please ensure Javascript is enabled for purposes of website accessibility

Why American Renal Associates Holdings Is Being Mauled Today

By Brian Feroldi – Updated Apr 16, 2019 at 10:39AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Traders flee after the company announces that its CFO has resigned and that some of its financial statements need to be restated. Here's what investors need to know.

What happened

Shares of American Renal Associates Holdings (ARA), a provider of dialysis services in the U.S., are sinking like a stone today after the company announced that its chief financial officer has resigned and that some of its financial statements need to be restated. The stock was down about 36% as of 11:14 a.m. EDT on Thursday.

So what

Here are the key details of today's announcement:

  • CFO Jason Boucher has resigned. Mark Herbers has been named interim CFO.
  • The board of directors has concluded that the company's financial statements for the fiscal years 2014, 2015, 2016, and 2017 should "no longer be relied upon" and need to be restated.
  • The company's Audit Committee continues to review the documents but has already identified a number of errors related to operating income and income before taxes. The company overreported and underreported these numbers by as much as $26 million in previous years.

The company also stressed that these are just preliminary findings and that they might change in time. The annual report for 2018 will be restated and released as soon as possible.

Shares are being thrashed in response to the news.

Check out the latest earnings call transcripts for the companies we cover.

Man holding hand over his face and talking on phone.

Image source: Getty Images.

Now what

Investors rely on accurate financial statements to make decisions, so today's news shouldn't be taken lightly.

Personally, I wouldn't touch American Renal's stock right now, no matter how "cheap" it may appear. There are simply too many unknowns. That's why my plan is to watch this story unfold from the safety of the sidelines and focus on other healthcare stocks that look far more compelling.

Brian Feroldi has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.